AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05701423
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05890664
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.
Trial: NCT06586216
Drug: PF-07817883
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT06236724
Drug: Asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by PO
Trial: NCT06790602
Drug: Cemiplimab Plus Gemcitabine
RxNorm normalized name: cemiplimab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cemiplimab Plus Gemcitabine
Trial: NCT06011954
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT06374836
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the OR, the patient will be sedated and have a transoesophageal echo (TEE) catether inserted, which is part of standard clinical care. When a patient becomes hypotensive and the attending anesthesiologist decides to infuse any of the following drugs (phenylephrine, ephedrine, norepinephrine, nitroprusside, or nicardipine), before infusion, the anesthesiolgist will acquire with TEE 10 beats of the thoracic ascending and descending aorta respectively. This is defined as one measurement. Five minutes after infusion the same measurement is repeated. A maximum of 10 measurements (5 before and 5 after infusion of a drug) per patient will be performed.~We want to explicitly mention that for study purposes the surgery or anesthesia will never be prolonged or modified, nor will any drugs be give for study purposes.
Trial: NCT06785090
Drug: Moxifloxacin 0.5% ophthalmic solution
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic, standard postoperative care regimen
Trial: NCT06785090
Drug: Dexamethasone phosphate 0.1%
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: steroid, standard postoperative care regimen
Trial: NCT06783790
Drug: Avapritinib, azacitidine, Venetoclax
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A: Induction therapy period: After patients were screened and enrolled, they began to receive 1-2 cycles of induction therapy, and the specific administration regimen was as follows: Avapritinib 100mg po qd D1-D14, azacitidine 35mg/m2 ih D1-D5, Venetoclax 100mg po qd D1-D14. The 28-day cycle was followed by curative effect evaluation at the end of each cycle. Patients who achieved complete remission entered the consolidation treatment stage.~B: Consolidation therapy period: Patients who achieved complete remission after 1-2 cycles of induction therapy continued to receive avapritinib 100mg/d po. monotherapy for consolidation therapy, with a cycle of 28 days and a total of 4 cycles
Trial: NCT04770896
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Trial: NCT04770896
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be administered once daily by mouth each day of every 21-day study treatment cycle. Participants with a baseline body weight of \< 60 kg will receive a daily dose of 8 mg. Participants with a baseline body weight of ≥ 60 kg will receive a daily dose of 12 mg.
Trial: NCT04770896
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib will be administered at a dose of 800 mg per day, i.e. two tablets of 200 mg swallowed by mouth twice daily (equivalent to a total daily dose of 800 mg) each day of every 21-day study treatment cycle.
Trial: NCT06575296
Drug: Revumenib
RxNorm normalized name: Revumenib
DrugBank: Revumenib (DB18515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06322706
Drug: ABSK021
DrugBank: BSK02 (DB17434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABSK021 oral
Trial: NCT06322706
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole oral
Trial: NCT03651895
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The Drug was administered 500 mg twice daily for one week and increased to 1g twice daily for the reminder of the 3 months.
Trial: NCT06584695
Drug: Transversus abdominis plane block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive transversus abdominis plane block with an oblique subcostal approach in the supine position. The anesthesiologist will place the linear ultrasound transducer obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The anesthesiologist will direct a 22G, 80 mm needle toward the transversus abdominis fascia and inject 25 mL of 0.25% bupivacaine between the rectus abdominis and transversus abdominis muscles along the subcostal line.
Trial: NCT06584695
Drug: External Oblique Intercostal Plane Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive external oblique intercostal block the patient will be in the supine position with their ipsilateral arm abducted, A linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib, with the orientation marker directed cranially. The skin will be sterilized, and the probe will be placed over the sixth rib medial to the anterior axillary line in a parasagittal orientation the in-plane technique with a 22G, 80 mm block needle will be used to inject 25 ml of 0.25% bupivacaine into the external oblique intercostal plane.
Trial: NCT04718415
Drug: sintilimab, paclitaxel, carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT06792214
Drug: Nirmatrelvir/ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paxlovid PO BID for 5 days + standard of care
Trial: NCT06792214
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Veklury IV daily for 5 days + standard of care
Trial: NCT04524390
Drug: Maralixibat
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small molecule inhibitor of the ileal bile acid transporter (IBAT)
Trial: NCT05489705
Drug: Mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per product label
Trial: NCT05489705
Drug: Non-mavacamten symptomatic oHCM therapy
RxNorm normalized name: Mavacamten
DrugBank: AVAC (DB05441)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label
Trial: NCT05374512
Drug: Dato-DXd
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental drug. Provided in 100mg vials. IV infusion.
Trial: NCT05374512
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion. Active comparator
Trial: NCT05374512
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion. Active comparator
Trial: NCT05374512
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion. Active comparator
Trial: NCT05374512
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion. Active comparator
Trial: NCT04617314
Drug: RC108
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.
Trial: NCT06014775
Drug: Anti-CD38 antibody Injection
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Trial: NCT05281510
Drug: Vesatolimod
RxNorm normalized name: Vesatolimod
DrugBank: Vesatolimod (DB12687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06477055
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib, 80mg, po, qd.
Trial: NCT06650709
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
Trial: NCT06650709
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
Trial: NCT06650709
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
Trial: NCT05653492
Drug: Sulforaphane
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing study one to four 30 mg/d tablets depending on weight
Trial: NCT04989803
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting chemotherapy administered intravenously
Trial: NCT06149559
Drug: rozanolixizumab
RxNorm normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rozanolixizumab solution for injection
Trial: NCT06283667
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
Trial: NCT06591390
Drug: Ticagrelor 90 MG
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Trial: NCT06591390
Drug: Cilostazol 100 MG
RxNorm normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Trial: NCT06548607
Drug: RD06-04 or RD06-05 CART Cell Injection
RxNorm normalized name: edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Trial: NCT04570423
Drug: Eflapegrastim
RxNorm normalized name: Eflapegrastim
DrugBank: Eflapegrastim (DB15001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflapegrastim supplied in prefilled, single-use syringes for SC injection.
Trial: NCT05419505
Drug: Antifibrinolytic Agent
RxNorm normalized name: ANTIFIBRINOLYTICS
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered by participants enrolled in Cohort 7.
Trial: NCT05155345
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
Trial: NCT05155345
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
Trial: NCT05910554
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients randomized to metformin will be assigned the active arm.
Trial: NCT05910554
Drug: Cellulose
RxNorm normalized name: Cellulose
DrugBank: Sodium cellulose phosphate (DB06776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to cellulose will be assigned the placebo arm.
Trial: NCT05236582
Drug: Herombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.
Trial: NCT04718376
Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Trial: NCT06772753
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active comparator for psychedelic effects
Trial: NCT06772753
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: psychoactive substance
Trial: NCT06772753
Drug: Dextromethorphan (DXM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: psychoactive substance
Trial: NCT06772753
Drug: Dimethyltryptamine (DMT)
RxNorm normalized name: Dimethyltryptamine
DrugBank: Dimethyltryptamine (DB01488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: psychoactive substance
Trial: NCT06772753
Drug: Methylenedioxymethamphetamine (MDMA)
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: psychoactive substance
Trial: NCT06772753
Drug: Tetrahydrocannabinol (THC)
RxNorm normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: psychoactive substance
Trial: NCT05874154
Drug: Botulinum toxin injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
Trial: NCT04272242
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04272242
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04272242
Drug: Rifapentine (RPT)
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06589921
Drug: Pirfenidone Modified-Release Tablets
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: take the tablet under fed condition, 1 tablet at a time, once a day.
Trial: NCT06589921
Drug: Pirfenidone Tablets
RxNorm normalized name: Pirfenidone Tablets
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ake the tablet under fed condition, 1 tablet at a time, three times a day.
Trial: NCT04721626
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative: The patient's dentition, or mandibular alveolus in the absence of dentition, will be brushed for two minutes with 0.12% chlorhexidine gluconate.~Intraoperative: The wound will be irrigated for 60 seconds with 0.05% chlorhexidine after it is irrigated with povidone-iodine.~Postoperative: Patients will swish and spit/suction 15mL 0.12% Chlorhexidine Gluconate (CHG) oral rinses for 30 seconds every six hours for two days (8 total administrations)
Trial: NCT04721626
Drug: Povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative: The oral cavity and oropharyngeal mucosa as well as the nasal vestibules will be coated with 5% povidone-iodine which will stand for at least three minutes prior to incision.~Intraoperative: The wound will be irrigated for 60 seconds with 10% povidone-iodine.
Trial: NCT06594016
Drug: Fosigotifator
RxNorm normalized name: Fosigotifator
DrugBank: Fosigotifator (DB19409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06604611
Drug: Colchicine 0.5 MG Oral Tablet Once Daily
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
Trial: NCT06291285
Drug: Decitabine-THU
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered immediate release tablets.
Trial: NCT06291285
Drug: Decitabine-THU
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered delayed release capsules.
Trial: NCT05727657
Drug: Satralizumab
RxNorm normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 120mg subcutaneous Day 0 and Day 14
Trial: NCT05498610
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will get 1 injections of semaglutide. It will be injected with a needle into a skin fold on the abdomen.~The study will last for a maximum of 72 days
Trial: NCT06486025
Drug: maintenance magnesium sulphate1g/h
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 1 g/h.
Trial: NCT06486025
Drug: maintenance magnesium sulphate2g/h
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive a routine loading infusion of 5 g of MgSO4 over 20 minutes, followed by a maintenance dose rate of 2 g/h.